Ionis Pharmaceuticals Inc (IONS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has a cash flow conversion efficiency ratio of -0.213x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-131.44 Million) by net assets ($617.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IONS net asset quality score to measure how much of total assets are equity-financed.
Ionis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IONS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ionis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
China Molybdenum Co. Ltd
F:D7N
|
0.041x |
|
RATIONAL Aktiengesellschaft
XETRA:RAA
|
0.126x |
|
SRF Limited
NSE:SRF
|
0.080x |
|
CTP N.V.
AS:CTPNV
|
0.016x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
0.007x |
|
Merlin Properties SOCIMI SA
LS:MRL
|
N/A |
Annual Cash Flow Conversion Efficiency for Ionis Pharmaceuticals Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Ionis Pharmaceuticals Inc from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Ionis Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $588.35 Million | $-500.95 Million | -0.851x | -7.07% |
| 2023-12-31 | $386.69 Million | $-307.51 Million | -0.795x | -66.05% |
| 2022-12-31 | $572.89 Million | $-274.37 Million | -0.479x | -1300.46% |
| 2021-12-31 | $772.00 Million | $30.80 Million | 0.040x | -6.30% |
| 2020-12-31 | $843.00 Million | $35.89 Million | 0.043x | -79.25% |
| 2019-12-31 | $1.69 Billion | $345.72 Million | 0.205x | -59.60% |
| 2018-12-31 | $1.19 Billion | $602.89 Million | 0.508x | +22.10% |
| 2017-12-31 | $418.72 Million | $174.15 Million | 0.416x | +136.94% |
| 2016-12-31 | $99.56 Million | $-112.11 Million | -1.126x | -1170.20% |
| 2015-12-31 | $200.79 Million | $21.12 Million | 0.105x | +331.52% |
| 2014-12-31 | $257.78 Million | $6.29 Million | 0.024x | -85.47% |
| 2013-12-31 | $378.39 Million | $63.49 Million | 0.168x | +1534.74% |
| 2012-12-31 | $182.77 Million | $1.88 Million | 0.010x | +101.53% |
| 2011-12-31 | $171.43 Million | $-114.80 Million | -0.670x | -157.51% |
| 2010-12-31 | $244.54 Million | $-63.59 Million | -0.260x | +27.56% |
| 2009-12-31 | $302.06 Million | $-108.44 Million | -0.359x | -117.65% |
| 2008-12-31 | $104.25 Million | $212.03 Million | 2.034x | -42.28% |
| 2007-12-31 | $10.24 Million | $36.09 Million | 3.524x | +748.16% |
| 2006-12-31 | $97.90 Million | $-53.23 Million | -0.544x | +97.65% |
| 2005-12-31 | $2.67 Million | $-61.74 Million | -23.167x | -1742.37% |
| 2004-12-31 | $-72.13 Million | $-101.75 Million | 1.411x | +199.25% |
| 2003-12-31 | $67.18 Million | $-95.47 Million | -1.421x | -134.12% |
| 2002-12-31 | $155.48 Million | $-94.38 Million | -0.607x | -2099.26% |
| 2001-12-31 | $223.10 Million | $-6.16 Million | -0.028x | +92.10% |
| 2000-12-31 | $66.37 Million | $-23.19 Million | -0.349x | +99.42% |
| 1999-12-31 | $800.00K | $-48.40 Million | -60.500x | -832.28% |
| 1998-12-31 | $-4.20 Million | $-34.70 Million | 8.262x | +1499.71% |
| 1997-12-31 | $34.90 Million | $-20.60 Million | -0.590x | -62.60% |
| 1996-12-31 | $58.40 Million | $-21.20 Million | -0.363x | -82.47% |
| 1995-12-31 | $75.90 Million | $-15.10 Million | -0.199x | +39.79% |
| 1994-12-31 | $46.00 Million | $-15.20 Million | -0.330x | -26.34% |
| 1993-12-31 | $58.50 Million | $-15.30 Million | -0.262x | +46.34% |
| 1992-12-31 | $39.80 Million | $-19.40 Million | -0.487x | -1820.50% |
| 1991-12-31 | $59.10 Million | $-1.50 Million | -0.025x | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more